Description: Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Piper Sandler Healthcare Conference on Tuesday, Dec. 2, 2025, beginning at approximately 10:00 a.m. EST in New York, NY.

Description: Solventum (SOLV) has just unveiled a substantial share buyback initiative, with the board authorizing the repurchase of up to $1 billion in common stock. The program, which carries no time limit, could reshape the company’s capital structure over time. See our latest analysis for Solventum. Solventum’s $1 billion buyback announcement comes after a strong year, with the share price up 26.5% year-to-date and a 16.7% gain in the past month alone. Investors appear to be warming up to the...

Description: Alphabet gains momentum as AI-driven growth in Cloud, Search and YouTube fuels rising customer adoption and revenue strength.

Description: Solventum views the acquisition as part of a broader growth transformation plan to reshape its portfolio and strengthen its balance sheet.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: The Relative Strength (RS) Rating for Solventum stock jumped into a higher percentile Friday, as it got a lift from 70 to 78.   How To Invest In Stocks In Both Bull And Bear Markets This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score.

Description: November has been NO-vember when it comes to tech stocks. Investors are shunning artificial-intelligence leaders and other momentum names. Investors seem to be embracing drug stocks, insurers, and medical equipment companies again.

Description: The company has stepped up its interest in M&A since making a $4.1 billion divestiture that strengthened its balance sheet.

Description: Solventum (NYSE: SOLV) announced today it has entered into a definitive agreement to acquire Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care for $725 million in cash plus up to $125 million in contingent cash payments based on the achievement of certain future milestones.

Description: Solventum (NYSE: SOLV) announced today its Board of Directors has approved a share repurchase program, which authorizes the Company to purchase up to $1 billion of the Company's outstanding common stock.

Description: Solventum Corporation recently reported third-quarter 2025 earnings, highlighting US$2.10 billion in revenue and a very large increase in net income to US$1.27 billion from US$122 million a year earlier, while raising its full-year earnings guidance. This sharp rise in profitability and improved outlook suggest that the company’s operational and portfolio strategies may be accelerating its financial performance faster than expected. We'll explore how Solventum's substantial net income jump...

Description: BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.

Description: Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.

Description: Solventum has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Description: Solventum’s third quarter results met Wall Street’s revenue expectations and exceeded consensus for non-GAAP earnings, with organic growth led by volume improvements across key segments. Management attributed the performance to execution on its three-phase transformation plan, including commercial restructuring, supply chain enhancements, and a sharpened product innovation process. CEO Bryan Hanson highlighted that “commercial and new innovation enhancements are delivering faster and more materi

Description: SOLV vs. DHR: Which Stock Is the Better Value Option?

Description: Ever wondered if Solventum is actually a value stock or just appears to be one at first glance? You're not alone. There is more to this story than just the sticker price. Solventum's stock has been on the move, climbing 9.1% over the past week and up 12.1% year-to-date. This could signal fresh optimism or a shift in the market's perception of risk. Much of the recent movement comes in the wake of Solventum's industry partnerships and strategic updates, which have caught the attention of both...

Description: DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

Description: Solventum (SOLV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Description: SOLV vs. DHR: Which Stock Is the Better Value Option?

Description: Healthcare solutions provider Solventum (NYSE:SOLV) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $2.10 billion. Its non-GAAP profit of $1.50 per share was 4.7% above analysts’ consensus estimates.

Description: Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.

Description: Solventum Corp (SOLV) reports robust earnings with increased EPS guidance, successful debt paydown, and strategic initiatives driving future growth.

Description: Solventum (NYSE:SOLV) has raised its earnings guidance for 2025 and is now projecting organic sales growth expectations at the higher end of its previous range. This upward revision signals confidence in the company’s ongoing strategy as its quarterly earnings approach. See our latest analysis for Solventum. Solventum’s raised 2025 guidance comes right as its stock weathers a tough patch, with a 1-year total shareholder return of -11.7%. Even so, recent announcements, including the upcoming...

Description: While the top- and bottom-line numbers for Solventum (SOLV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Solventum (SOLV) delivered earnings and revenue surprises of +4.90% and +0.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Healthcare solutions provider Solventum (NYSE:SOLV) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $2.10 billion. Its non-GAAP profit of $1.50 per share was 4.7% above analysts’ consensus estimates.

Description: On a per-share basis, the Maplewood, Minnesota-based company said it had profit of $7.22. Earnings, adjusted for one-time gains and costs, came to $1.50 per share. The results exceeded Wall Street expectations.

Description: Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2025.

Description: DENTSPLY SIRONA shares drop as Q3 earnings miss estimates and 2025 EPS guidance is cut amid segment weakness.

Description: Avanos Medical posts a Q3 earnings and sales beat, boosts 2025 outlook as Specialty Nutrition drives solid double-digit growth.

Description: McKesson posts a strong Q2 earnings beat but a slight sales miss, lifts its 2026 EPS outlook on solid specialty and tech segment growth.

Description: RGTI's Q3 results are likely to gain from U.S. funding clarity, new contracts and gains from its next-gen quantum system.

Description: Clover Health's Q3 sales soar 50%, but higher Insurance costs and a raised BER outlook weigh on investor sentiment.

Description: Cencora's Q4 results top estimates with 15% EPS growth and stronger margins, as GLP-1 demand and the RCA acquisition fuel solid segment gains.

Description: Fresenius Medical Care's Q3 earnings and revenues beat estimates, fueled by margin gains and solid organic growth across segments.

Description: Get a deeper insight into the potential performance of Solventum (SOLV) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Description: Healthcare solutions provider Solventum (NYSE:SOLV) will be announcing earnings results this Thursday afternoon. Here’s what to look for.

Description: Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.

Description: Dentsply Sirona's Q3 results may reveal ongoing softness in U.S. demand and orthodontic segments despite steady cost control.

Description: McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.

Description: Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, Nov. 12, 2025, beginning at approximately 11:20 a.m. EST in New York, NY.

Description: Recent analyst updates for Solventum stock show the Fair Value Estimate remains steady at $85.11. This signals confidence in the company’s long-term outlook. While the discount rate has seen a slight increase, modestly reflecting higher perceived risk or market conditions, expectations for revenue growth have improved just enough to suggest a gradually more optimistic perspective. As the narrative around Solventum continues to unfold alongside these nuanced adjustments, stay tuned to learn...

Description: DXCM posts double-digit Q3 growth and raises 2025 revenue outlook, but shares tumble despite strong CGM momentum and innovation updates.

Description: Stryker's Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.

Description: AVTR's Q3 earnings and revenue fell short of estimates, leading the company to cut its full-year 2025 outlook.

Description: DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.

Description: TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results.

Description: OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.

Description: Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.

Description: Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips; shares fall despite strength in Pharma and Advanced Surgery.

Description: Cardinal Health delivered a strong Q1 beat and lifted its 2026 EPS outlook, fueled by broad-based growth and rising profits across all business segments.

Description: Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Solventum recently appointed Heather Knight as Chief Commercial Officer, a newly established role overseeing global commercial and R&D operations across key business segments, effective November 10, 2025. Ms. Knight's extensive MedTech leadership background and the departure of a senior executive signal a significant shift in Solventum's commercial and operational leadership at a time of softening revenue growth and cautious forecasts. We will examine how this leadership transition and...

Description: GE HealthCare's Q3 results show steady revenue growth as strong imaging and diagnostics offset tariff and margin pressures.

Description: Solventum (SOLV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: While the S&P 500 is up 24.4% since April 2025, Solventum (currently trading at $71.44 per share) has lagged behind, posting a return of 8.1%. This may have investors wondering how to approach the situation.

Description: Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.

Description: GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.

Description: If you’ve been watching Solventum’s share price lately, you’re probably weighing your next move, especially since the stock hasn’t exactly been in straight-up mode. After climbing 8.4% year-to-date, Solventum gave up 1.0% over the past week and is basically flat for the last month. Over the last year, shares have dipped by 2.4%, painting a picture that’s far from dramatic but definitely worth a closer look. These moves have come as the company navigates some pivotal transitions and headlines,...

Description: Solventum will release its third-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Description: Chris Barry, group president of medsurg at Solventum, is leaving the company at the end of the year in connection with Knight’s arrival.

Description: SOLV vs. MEDP: Which Stock Is the Better Value Option?

Description: Solventum (NYSE: SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson.